Introduction
SMARCA2) as its catalytic (ATPase) subunit (7, 22) . BRG1 and BRM play complementary roles, as indicated by the observation that Brm-deficient mice develop normally but exhibit up-regulated BRG1 expression in somatic cells (23) . Brg1-null heterozygous mice spontaneously develop mammary tumors, and specific alleles of BRG1 are associated with cancer predisposition in humans (24) . Therefore, BRG1/Brg1 acts as a tumor-suppressor gene (25). The complementary roles of BRG1 and BRM, coupled with the involvement of the SWI/SNF complex in multiple critical cellular functions, suggest that BRG1 and BRM might have a synthetic-lethal relationship; therefore, we examined the ability of BRM inhibition to specifically kill BRG1-deficient tumor cells. In addition, to address the potential significance of BRM-inhibitory therapies, we examined the characteristics of BRG1-deficient NSCLCs, including the mutually exclusive relationship between BRG1 deficiencies and mutations in therapeutic target genes (EGFR and DDR2 mutations, ALK fusions, and FGFR1 amplifications) (Fig. 1A) .
Materials and Methods

NSCLC cohort
Surgical specimens from 103 patients with NSCLC (51 adenocarcinomas and 53 squamous-cell carcinomas), who received surgical resection at the National Cancer Center Hospital (Tokyo, Japan), between 1997 and 2007, were analyzed ( Table 1, Supplementary Materials and Methods). The study was approved by the institutional review board of the National Cancer Center.
Immunohistochemical analysis of BRG1 and BRM
Immunohistochemical analysis was performed on tissue microarray sections obtained from anonymized NSCLC samples. The methods used for immunohistochemical staining and the criteria for BRG1 and BRM positivity are described in the Supplementary Materials and Method. Specific staining for BRG1 and BRM was confirmed by immunoblot analysis of cancer cell lines ( Supplementary   Fig. S1 ).
Examination of driver gene mutations
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Mutations in all DDR2 coding regions in squamous cell lung carcinoma samples were examined by targeted genome capture and massively parallel sequencing using an Ion PGM sequencing system and the Ion TargetSeq Custom Enrichment Kit (Life Technologies). EML4-ALK and KIF5B-ALK fusions were screened by immunohistochemistry using an anti-ALK antibody (Abcam; 5A4), followed by confirmation via reverse-transcriptase polymerase chain reaction and/or fluorescence/chromogenic in situ hybridization (27) . RET and ROS1 fusions (in cases for which RNA samples are available) were examined by RT-PCR (2, 4) . harboring truncating BRG1 mutations, whereas H520, HeLa, LK2, H460, U2OS, and HT1080 carry wild-type BRG1 (13, 17) . The BRG1 mutation status of all cell lines used in this study is given in Supplementary Table S1 . Alterations in BRG1 and other colorectal cancer cells (16) , was estimated using the Polyphen and Polyphen2 programs.
The substitutions in HCT116 cells are thought to abrogate ATPase activity, but those in WiDr cells are benign (Supplementary Table S3 ).
Short interfering (si) RNA
ON-TARGET plus SMARTpool siRNA (Dharmacon) was used in this study.
To knock down the BRM protein, cells were transfected with siBRM (Cat No: 6597: SMARCA4) using Lipofectamine RNAiMAX (Invitrogen). Non-targeting siRNA (L-001810-10) was used as a negative control.
Establishment of cells expressing doxycycline-inducible short hairpin (sh) BRM
To achieve doxycycline (dox)-inducible knockdown of BRM, a lentiviral vector-based shRNA-mediated conditional gene-expression system (established by 
Immunoblot analysis
Immunoblotting was performed as previously described (8) . The antibodies used in the present study are listed in the Supplementary Materials and Methods.
Cell survival assay
The effect of BRM knockdown on the survival of BRG1-deficient (undetectable by immunoblot analysis) and BRG1-proficient (detectable by immunoblot analysis) cancer cells was evaluated using clonogenic survival assays. Because non-cancerous fibroblasts do not form colonies on culture plates, the viability of these cells was determined by examining cellular ATP levels using the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega). The detailed procedures for these assays were described in the Supplementary Materials and Methods.
Complementation assay
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Cell-cycle analysis
Cells were trypsinized, centrifuged, washed in PBS, and fixed in ice-cold 70% ethanol. The cells were then centrifuged again, incubated with PBS containing 200 μg/ml RNase A and 5 μg/ml propidium iodide, and analyzed for cell-cycle distribution by Guava flow cytometry (Millipore).
Senescence-associated β-galactosidase (SA-β-gal) staining SA-β-gal staining was performed using the Senescence β-galactosidase The experiment was performed in duplicate.
Mouse xenograft model
The effect of BRM ablation on the growth of H1299-shBRM and 
Results
Characteristics of BRG1-deficient NSCLCs
We first examined the characteristics of BRG1-deficient NSCLCs. Because BRG1 has been reported to play a role in cell differentiation (31) , the examined cases were selected in order to include similar numbers of adenocarcinomas and squamous-cell carcinomas of the three differentiation grades (well; moderately; and poorly differentiated) ( Table 1) . This approach allowed an efficient analysis of the association between BRG1 expression and tumor differentiation. Immunohistochemical analysis revealed that BRG1 protein expression was either low or absent in 16/103 (15.5%) NSCLCs (Fig. 1B, C) . Low or absent BRG1 expression was more prevalent in poorly differentiated tumors ( Table 1 and Fig. 1D) , and was also prevalent in males and smokers. Mutational analysis of BRG1 and BRM in 16 cases negative for BRG1 staining revealed that one case had nonsense BRG1 mutations (Supplementary Fig. S2 ), whereas the remaining 15 did not, implying that both genetic alterations and epigenetic silencing of the BRG1 gene can cause BRG1 deficiency, as previously reported (18) . On the other hand, deleterious BRM mutations were not detected in these 16 cases including five that were negative for BRM staining. the two therapeutic targets (EGFR mutation and ALK fusion) (Fig. 1D, Table 1 ). We also analyzed other driver gene mutations, RET and ROS1 fusions (2) (3) (4) , in the nine BRG1-deficient cases for which tumor tissue RNA was available, but we detected no fusions. Recent whole-genome analyses have also suggested that BRG1 mutations are prevalent in tumors without EGFR mutations or ALK fusions (32, 33) (Supplementary Table S4 ). In addition, all the BRG1-deficient cases were also negative for two other alterations, FGFR1 amplifications and DDR2 mutations (5, 6) ( Fig. 1D , Table 1 , Supplementary Fig. S3 ). These findings suggest that most BRG1-deficient NSCLCs are not suitable for current molecularly targeted therapies based on tyrosine kinase inhibitors (1) . Of the 16 BRG1-deficient cases, 10 (62.5%, 9.7% of all cases studied) expressed BRM.
Driver gene mutations in BRG1-deficient NSCLCs
BRM-dependent growth of BRG1-deficient cancer cells
We then compared the effect of siRNA-mediated BRM ablation on in vitro growth of BRG1-deficient (n = 10) and BRG1-proficient (n = 8) cancer cell lines, using a clonogenic survival assay ( Table S2 ) (13, 17) . Of the remaining two BRG1-deficient cell lines, we detected a homozygous nonsense mutation in one (HCC515) by targeted genome capture sequencing ( Supplementary Fig. S2 ), but no BRG1 mutation in the other (II-18). On the other hand, BRG1-proficient cancer cells did not harbor such deleterious BRG1 mutations (except HCT116 cells, which harbor a heterozygous missense mutation that is likely to disrupt the BRG1 ATPase domain (15)).
We observed suppression of colony formation in all BRG1-deficient cells tested, but not in BRG1-proficient lines other than HCT116 ( by Student's t-test). The BRM protein was undetectable, or detectable only at trace levels, in three BRG1-deficient cell lines, A427, H522, and H1703 ( Fig. 2A,   Supplementary Fig. S4A ). These findings are consistent with a report showing that a fraction of lung-cancer cells lack, or express at low levels, both BRG1 and BRM (14) Research. ( Fig. 1B) . Conceivably, the effect of siRNA-mediated BRM knockdown in these three cell lines was less evident than in the other seven. Thus, among BRG1-deficient cell lines, the suppression of colony formation by BRM knockdown was more prominent in cell lines that originally expressed the BRM protein (P = 4.5 × 10 -9 by Student's t-test) (Fig. 2D) .
BRM knockdown did not affect the growth of the non-cancerous fibroblast cell lines HFL-1 and MRC-5, which express both BRG1 and BRM (Fig. 3A, B) . Wild-type BRG1 cDNA complemented the sensitivity of BRG1-deficient H1299 cells to BRM siRNA-mediated growth inhibition (Fig. 3C, D) , whereas cDNA of an ATPase mutant with a disrupted ATP-binding pocket, BRG1 K785A (30), did not (BRG1 K785A is indicated as KA in Fig. 3C , D). These results indicated that BRG1-deficient cancer cells depend on BRM for growth, and that this phenotype is caused by a lack of BRG1 ATPase activity.
BRM depletion induces senescence in BRG1-deficient cancer cells
To examine the long-term effects of BRM depletion, we prepared H1299 Fig. S5 ). We next examined the mechanism underlying growth inhibition in H1299-shBRM cells. Seven days after dox treatment, H1299-shBRM cells, but not HeLa-shBRM cells, exhibited G1 arrest with an enlarged and flattened morphology, suggesting senescence (Fig. 4A, Supplementary Fig. S6 ). Biomarkers of senescence (35, 36) (p21/CDKN1A expression, SA-β-gal staining, and SAHF) were observed in dox-treated H1299-shBRM cells, but not in HeLa-shBRM cells (Fig. 4B,   C ). Dox treatment did not affect the proportion of cells in sub-G1 phase or the number of cells exhibiting distinct nuclear lobation, indicating that ablation of BRM does not induce apoptosis or mitotic catastrophe (37) (Fig. 4A, C) . Senescence is an irreversible state of growth arrest that is maintained by p21 (38); therefore, we examined p21
Research. expression in H1299-shBRM cells in which BRM was re-expressed after dox removal (Fig. 4D) . In these cells, p21 expression was maintained at the level observed in BRM knockdown cells. Consistent with this, cells re-expressing BRM exhibited suppressed clonogenic growth activity. siRNA-mediated knockdown of BRM caused significant increases in SA-β-gal positivity and the number of cells in G1 phase in three BRG1-deficient NSCLC cell lines (H1299, A549, and H157), but not in three BRG1-proficient NSCLC cell lines (H520, LK2, and H460) (Fig 4E, Supplementary   Fig. S7 ). Taken together, these results suggest that BRM knockdown specifically suppresses the growth of BRG1-deficient cells by inducing senescence.
BRM-dependent growth of BRG1-deficient cancer cells in vivo
The number of BRM-depleted H1299-shBRM cells was ~1,000 times lower than that of non-depleted cells after 4 weeks of culture, whereas the number of HeLa-shBRM cells did not change (Fig. 5A) . This observation suggests that inhibition of BRM specifically suppresses the long-term growth of BRG1-deficient cells (i.e., over at least a month). To further confirm these data under more physiologically relevant conditions, we introduced H1299-shBRM and H1299-shControl cells into an in vivo conditional RNAi model (Fig. 5B) . BALB/c-nu/nu mice were injected subcutaneously with H1299-shBRM or H1299-shControl cells. After 3 weeks, when the injected cells had formed tumor nodules measuring approximately 100 mm 3 , the animals were randomly divided into two groups and fed a diet containing dox (200 ppm) or a control diet for 1 month. In dox-fed mice, the H1299-shBRM xenografts were significantly smaller than the H1299-shControl xenografts.
Discussion
This study suggests that BRM is a novel therapeutic target for synthetic-lethality therapy of BRG1-deficient cancers. To the best of our knowledge, this is the first report proposing a therapeutic strategy that specifically targets and kills cancer cells harboring inactivating mutations in SWI/SNF chromatin-remodeling genes.
In the future, the utility of this strategy needs to be further validated in vivo using multiple lines of BRG1-deficient and -proficient cancer cells.
In our cohort, all of the BRG1-deficient tumors were negative for EGFR 
mutations and ALK fusions, both of which can be targeted by existing molecular therapies utilizing tyrosine kinase inhibitors (1). This negative association of BRG1-inactivating mutations with therapeutic target mutations is consistent with two recent genome-wide mutation analyses of lung adenocarcinoma (32, 33) ( Supplementary Table S4 ). Indeed, BRG1-deficient NSCLC cell lines are resistant to tyrosine kinase inhibitors that target EGFR (e.g., A549, H1819, and H1299) (39) or ALK (A549) (40). Furthermore, those BRG1-deficient tumors were also negative for The results of this study demonstrate that BRG1 and BRM have a synthetic-lethal relationship. BRG1 functions as a key enzyme in SWI/SNF chromatin remodeling during transcription, as well as in DNA double-strand break repair (7, 8, 31) .
BRG1 is involved in the expression of genes that regulate cell growth and stem-cell properties. However, a preliminary study indicated that the expression of representative genes, including those encoding E2F1 and cyclin D1, does not differ significantly between BRG1-proficient and -deficient cells depleted of BRM. Thus, the mechanisms underlying the synthetic-lethal relationship between BRG1 and BRM remain unknown.
Of concern is the subset of NSCLC cases (5.8%; Fig. 1B ) that lack both BRG1 and BRM expression (14, 22, 42) . BRM deficiency is likely to be due to epigenetic alterations as previously reported (43). The existence of these cases suggests that a portion of BRG1-deficient tumors will not respond well to therapies that target BRM, as suggested by our experiment using cancer cell lines (Fig. 2B) . Such tumors may have acquired the ability to maintain cell growth through complementation by chromatin-remodeling proteins other than BRG1 and BRM, although our preliminary 
analysis did not reveal complementation by over-expression of other SWI/SNF and chromatin-remodeling proteins (Supplementary Fig. S4B) . Studies of the molecular mechanisms underlying the maintenance of cell growth in the absence of both BRG1 and BRM would be valuable, because it is possible that BRG1-deficient cells could acquire resistance to BRM-targeted therapy.
The pathogenic significance of inactivating somatic mutations in genes encoding the subunits of the SWI/SNF chromatin-remodeling complex in human cancers is largely unknown (7). This study sheds light on this issue by demonstrating that BRG1-deficient tumors are often poorly differentiated. A previous report showed that BRG1 promotes cell differentiation, i.e., the inactivation of BRG1 enables cancer cells to maintain undifferentiated gene-expression programs (31) . Therefore, loss of BRG1 function may be responsible for tumor dedifferentiation. Our results also indicated that BRG1 deficiency is prevalent in tumors of males and smokers ( Table 1) , consistent with recent genome-wide mutational studies ( Supplementary Table S5 ) (40, 41). Therefore, BRG1 deficiency may play a role in lung carcinogenesis preferentially in male and/or smokers, although the underlying mechanisms remain unclear.
Taken together, the results of this study identify BRM as a candidate target molecule for synthetic-lethal therapy of BRG1-deficient lung cancers.
Immunohistochemical analyses revealed that approximately 10% of NSCLCs are BRG1-deficient and BRM-proficient, and are therefore predicted to respond to therapies that target BRM. Inactivation of BRG1 also occurs in other cancers, including pancreatic, skin, and brain cancers (44). BRG1 was recently identified as a gene that is frequently mutated in medulloblastomas (subgroup 3) (45), which lack known driver gene mutations (19, 20) . Thus, it is possible that therapies targeting BRM will be suitable for treating a variety of cancers. Inactivating mutations in chromatin-remodeling genes other than BRG1, such as PBRM1/BAF180, ARID1A/BAF250A, and ARID2/BAF200, have been identified in several common cancers. Synthetic lethality-based therapeutic strategies targeting tumors harboring these mutations warrant further study.
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